Bös M, Bauer J
Klinik für Epileptologie, Universitätskliniken Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany.
Nervenarzt. 2007 Dec;78(12):1425-9. doi: 10.1007/s00115-007-2333-x.
We analysed patients with focal epilepsies treated with zonisamide (ZNS) as add-on treatment to topiramate (TPM) and other antiepileptic drugs (mean 2). Twenty-five patients were evaluated, and follow-up data were available in 19 (12 women, seven men, mean age 34 years). The mean time until first follow-up investigation was 17 weeks. At that point in time the mean ZNS dosage was 344 mg and mean TPM dosage was 398 mg. Eight patients (42%) achieved seizure frequency reduced by at least 50%. Six patients (31%) reported side effects, especially cognitive impairment and weight loss (>5 kg) in two patients. In the further course of treatment, ZNS was discontinued in two of three patients because of cognitive impairment. We conclude that add-on treatment including ZNS and TPM can not be recommended for chronic treatment of epilepsy.
我们分析了使用唑尼沙胺（ZNS）作为托吡酯（TPM）及其他抗癫痫药物（平均两种）的附加治疗的局灶性癫痫患者。共评估了25例患者，其中19例（12名女性，7名男性，平均年龄34岁）有随访数据。首次随访调查的平均时间为17周。此时ZNS的平均剂量为344毫克，TPM的平均剂量为398毫克。8例患者（42%）发作频率至少降低了50%。6例患者（31%）报告有副作用，尤其是两名患者出现认知障碍和体重减轻（超过5千克）。在治疗的后续过程中，三名患者中有两名因认知障碍停用了ZNS。我们得出结论，不推荐ZNS和TPM联合进行癫痫的长期治疗。
